Clinical Trial

Rupatadine in Patients With Ulcerative Colitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Ulcerative colitis (UC) is a chronic inflammatory condition that primarily targets the large intestine. Although substantial progress has been made in treatment modalities-especially with the development of immunomodulatory drugs and biologic therapies-managing UC continues to present significant challenges. At present, there is no definitive cure, and current treatment strategies are largely focused on controlling inflammation, relieving symptoms, and halting disease progression
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-06; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-09-20
Trial Details
NCT Number NCT07064707
Lead Sponsor Alexandria University
Collaborators: Prof. Dr. Ahmed Ibrahim Mohammed El Mallah, faculty of pharmacy, Alexandria University., Assoc. Prof. Dr. Noha Alaa Eldin Hassan Hamdy, Faculty of pharmacy, Alexandria University., Assoc. Prof. Dr. Ibrahim Fathi Amer, Faculty of Medecine, Kafr Elsheikh University.
Conditions Ulcerative Colitis
Enrollment 60 participants
Start Date 2025-07-15
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-10-21 (estimated)
Updated on ClinicalTrials.gov 2025-11-19